Navigation Links
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Date:1/26/2009

ABBOTT PARK, Ill., Jan. 26 /PRNewswire-FirstCall/ -- Data published online today in Circulation from the SPIRIT III U.S. pivotal trial evaluating the XIENCE V(TM) Everolimus Eluting Coronary Stent System demonstrated that Abbott's market-leading XIENCE V outperforms the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) in reducing major adverse cardiac events (MACE) at two years. In the SPIRIT III trial of 1,002 patients, XIENCE V demonstrated a 45 percent reduction in the risk of MACE, and a 40 percent reduction in the risk of cardiac death or heart attack (myocardial infarction, or MI) at two years in patients treated with XIENCE V compared to those treated with TAXUS. Additionally, at two years the study demonstrated a 32 percent reduction in the risk of target vessel failure (TVF, cardiac events related to the treated vessel) for XIENCE V compared to TAXUS. These published results were first presented in May 2008 at the EuroPCR Congress in Barcelona.

"As published in Circulation, the SPIRIT III study results demonstrate that the clinical benefits of XIENCE V continue to improve between one and two years of follow-up after stent implantation compared to TAXUS," said Gregg W. Stone, M.D., Columbia University Medical Center; chairman, Cardiovascular Research Foundation, New York; and principal investigator of the SPIRIT III trial. "These data reinforce our earlier findings demonstrating the excellent angiographic and clinical results with the XIENCE V stent, resulting in fewer heart attacks and repeat reinterventions."

The SPIRIT III trial demonstrated the following key results for XIENCE V at two years:

-- A 45 percent reduction in the risk of MACE compared to TAXUS (7.3 percent for XIENCE V vs. 12.8 percent for TAXUS, p-value=0.004)*. MACE is an important composite clinical measure of safety and effic
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
2. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
5. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
11. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 In response to an ... 2009, in which the Agency recommended that healthcare ... (SS1) sterile processing system, hospitals throughout the U.S. ... alternatives to that product. According to the FDA, ... SS1 that may affect the safety or the ...
(Date:12/14/2009)... 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... Drug Application (NDA) for Staccato® loxapine (AZ-004) to the ... an inhalation product candidate being developed for the rapid ... disorder. The IND for Staccato loxapine ... "AZ-004 has delivered a predictable and consistent safety and ...
(Date:12/14/2009)... -- Cardinal Health today announced that executives of the ... Goldman Sachs CEO Unplugged Conference on ... Conference Center in New York. 28th Annual ... Noon EST at the Westin St. Francis Hotel in ... will discuss Cardinal Health,s diverse products and services, company ...
Breaking Medicine Technology:ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Cardinal Health Executives to Speak at Two Investor Events in January 2New National Nurse Talk Radio Show Takes Off with Humor Health and a Voice for the Patient Advocate 61727 1New National Nurse Talk Radio Show Takes Off with Humor Health and a Voice for the Patient Advocate 61727 2New National Nurse Talk Radio Show Takes Off with Humor Health and a Voice for the Patient Advocate 61727 3Duplicate File Detective v3 0 Provides Enterprise Grade Duplicate File Management 61725 1Duplicate File Detective v3 0 Provides Enterprise Grade Duplicate File Management 61725 2Spray May Delay Ejaculation 61723 1Spray May Delay Ejaculation 61723 2
... WEST CHESTER, Ohio, Jan. 7 AtriCure, Inc.,(Nasdaq: ... a leader in cardiac surgical,ablation products, today announced ... products, which physicians have adopted to,treat atrial fibrillation ... by Dr. James H. Wudel, a prominent cardiac ...
... Fovea Pharmaceuticals SA, which, last,December 2007, raised ... announced that,its product, Recombinant human rod-derived cone ... Medicinal Product from the,European Commission, following the ... Evaluation of Medicinal Products (EMEA) Committee for ...
Other Medicine Technology:Positive Results Published Using AtriCure Minimally Invasive Products 2Positive Results Published Using AtriCure Minimally Invasive Products 3Positive Results Published Using AtriCure Minimally Invasive Products 4Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa 2Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa 3
(Date:12/14/2009)... But the bump in odds is small and shouldn,t ... (HealthDay News) -- Older women who take antidepressants may ... stroke and death compared to women not on the ... can be different from clinical significance," stressed Dr. Jordan ... Medical School, and lead author of a report in ...
(Date:12/14/2009)... team of scientists from the UC San Diego School ... a protein switch that helps prevent liver damage, including ... better understanding of how the protein, TAK1, works could ... disease and cancer. , "TAK1 appears to be ... Brenner, MD, professor of medicine and Dean of the ...
(Date:12/14/2009)... and highly stigmatized, according to psychiatrists Charles F. ... So these Washington University physicians have written a ... Psychiatry," Zorumski and Rubin, who have more than ... helping patient families, say some of the problems ... a lack of understanding psychiatry and what psychiatrists ...
(Date:12/14/2009)... Study links perceived age to physical, mental functioning , ... look younger than their age tend to live longer ... new study suggests. , The finding came from research ... who were given physical and cognitive tests and then ... at the photos and indicated the age they perceived ...
(Date:12/14/2009)... Lesions Quickly and Accurately for Biopsy , ... ... Dilon Diagnostics announced today that the U.S. Food and ... system for molecular imaging biopsy guidance. , , ,GammaLMc® ... 6800 Gamma Camera. The GammaLMc® (GL) system will help doctors ...
Breaking Medicine News(10 mins):Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3Health News:Scientists uncover protective mechanism against liver cancer 2Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3Health News:Looking Younger Than Your Age May Mean Longer Life 2Health News:Dilon Diagnostics Gamma-Guided Localization System Cleared by FDA 2
... IPC The Hospitalist Company, Inc. (Nasdaq: IPCM ), a leading national physician group practice company, ... be held on May 18th and 19th in Boston, MA. , ... and COO, Date: ... Time: ...
... 5 The following is a statement by Joon ... of Swine Flu Fear (SFF) in the United States ... over a menace that authorities around the world are ... SFF is highly contagious, and even a brief exposure ...
... UVC to fan coils, unit ventilators and indoor air ... for Air Handlers from Steril-Aire, Inc. may be used ... microorganisms including flu viruses, bacteria and mold. The ... coil units, unit ventilator systems and indoor air handlers ...
... can stimulate the appetite particularly among hospitalized seniors ... in The Gerontologist . , "The more social ... the better food intake will be," says Danielle St-Arnaud ... Department of Nutrition, St-Arnaud McKenzie conducted the study with ...
... U.S. Attorney A. Brian Albritton announces the ... Prosecution Agreement concerning WellCare Health Plans, Inc. (WellCare). ... executives and employees, in an elaborate scheme to ... Healthy Kids Corporation ("Healthy Kids" or FHKC) program ...
... Americans Month, the American Foundation for the Blind (AFB) has ... falls among seniors with vision loss. This year,s theme ... for a Better Tomorrow" -- reflects the ... throughout the country that are helping older adults have better ...
Other Medicine News:Health News:IPC The Hospitalist Company, Inc. to Present at Deutsche Bank's 34th Annual Health Care Conference 2Health News:Swine Flu Fear (SFF) Now a Pandemic 2Health News:New UVC Kit Destroys Microorganisms Including flu Viruses, Bacteria and Mold 2Health News:Charges Filed Against WellCare Health Plans, Inc.; WellCare Enters Into Deferred Prosecution Agreement, Agrees to Pay $80 Million in Restitution and Forfeiture 2Health News:Charges Filed Against WellCare Health Plans, Inc.; WellCare Enters Into Deferred Prosecution Agreement, Agrees to Pay $80 Million in Restitution and Forfeiture 3Health News:Charges Filed Against WellCare Health Plans, Inc.; WellCare Enters Into Deferred Prosecution Agreement, Agrees to Pay $80 Million in Restitution and Forfeiture 4Health News:Charges Filed Against WellCare Health Plans, Inc.; WellCare Enters Into Deferred Prosecution Agreement, Agrees to Pay $80 Million in Restitution and Forfeiture 5Health News:Preventing Dangerous Slips and Falls: The American Foundation for the Blind Launches New Video Series on Staying Safe at Home 2
... The latest from the leader in automatic ... and modern approach to slide staining, ending ... peripheral blood smears, bone marrow and other ... the Aerospray stainer becomes a superb cytocentrifuge ...
HMS 760 Robot Stainer. Version includes display....
Cholesterol, Total. An automated analyzer test kits....
For the quantitative determination of total cholesterol in serum....
Medicine Products: